NO2760138T3 - - Google Patents

Info

Publication number: NO2760138T3
Authority: NO; Norway

Application number

NO14160512A

Other languages

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2012-10-01

Filing date

2012-01-12

Publication date

2018-08-04

2012-01-12 Application filed filed Critical

2018-08-04 Publication of NO2760138T3 publication Critical patent/NO2760138T3/no

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/005—Glycopeptides, glycoproteins
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2806—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD2
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
- C07K16/2842—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta1-subunit-containing molecules, e.g. CD29, CD49
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/582—Recycling of unreacted starting or intermediate materials

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Immunology (AREA)
Life Sciences & Earth Sciences (AREA)
Genetics & Genomics (AREA)
Biochemistry (AREA)
General Health & Medical Sciences (AREA)
Molecular Biology (AREA)
Biophysics (AREA)
Medicinal Chemistry (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Engineering & Computer Science (AREA)
Wood Science & Technology (AREA)
Zoology (AREA)
Biotechnology (AREA)
Bioinformatics & Cheminformatics (AREA)
Microbiology (AREA)
General Engineering & Computer Science (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Peptides Or Proteins (AREA)
Biomedical Technology (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Cell Biology (AREA)

NO14160512A 2012-10-01 2012-01-12 NO2760138T3 (ko)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US201261708554P	2012-10-01	2012-10-01

Publications (1)

Publication Number	Publication Date
NO2760138T3 true NO2760138T3 (ko)	2018-08-04

Family

ID=49354940

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO14160512A NO2760138T3 (ko)	2012-10-01	2012-01-12

Country Status (27)

Country	Link
US (2)	US20150259425A1 (ko)
EP (1)	EP2904092B1 (ko)
JP (1)	JP6351598B2 (ko)
KR (1)	KR102182885B1 (ko)
CN (1)	CN104797707A (ko)
AU (1)	AU2013327681B2 (ko)
BR (1)	BR112015007319B1 (ko)
CA (1)	CA2886753C (ko)
CY (1)	CY1119602T1 (ko)
DK (1)	DK2904092T3 (ko)
EA (1)	EA201590550A1 (ko)
ES (1)	ES2646594T3 (ko)
HK (1)	HK1207394A1 (ko)
HR (1)	HRP20171753T1 (ko)
HU (1)	HUE034896T2 (ko)
IL (1)	IL237916A0 (ko)
IN (1)	IN2015DN02630A (ko)
LT (1)	LT2904092T (ko)
ME (1)	ME02882B (ko)
MX (1)	MX366106B (ko)
NO (1)	NO2760138T3 (ko)
PL (1)	PL2904092T3 (ko)
PT (1)	PT2904092T (ko)
RS (1)	RS56641B1 (ko)
SG (2)	SG11201502339YA (ko)
SI (1)	SI2904092T1 (ko)
WO (1)	WO2014055370A1 (ko)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2926588C (en)	2013-10-16	2020-07-21	Oncobiologics, Inc.	Buffer formulations for enhanced antibody stability
US10011657B2 (en)	2014-10-31	2018-07-03	Abbvie Biotherapeutics Inc.	Anti-CS1 antibodies and antibody drug conjugates
WO2016118707A1 (en)	2015-01-21	2016-07-28	Oncobiologics, Inc.	Modulation of charge variants in a monoclonal antibody composition
JP2019500878A (ja) *	2016-01-06	2019-01-17	オンコバイオロジクス，インコーポレイティド	モノクローナル抗体組成物中の高分子量種、酸性荷電種、及び断片の低減
EP3400241B1 (en)	2016-01-06	2020-07-22	Outlook Therapeutics, Inc.	Modulation of afucosylated species in a monoclonal antibody composition
CN109563161A (zh)	2016-02-03	2019-04-02	安口生物公司	用于提高抗体稳定性的缓冲制剂
EP3420072A4 (en) *	2016-02-22	2019-08-28	Agency for Science, Technology and Research	CELL CULTURE MEDIUM
CN110121359A (zh) *	2016-11-11	2019-08-13	怀特黑德生物制剂研究所	人血浆培养基
CN112566643A (zh)	2018-06-12	2021-03-26	加利福尼亚大学董事会	用于治疗癌症的单链双特异性嵌合抗原受体
CN111944050B (zh) *	2020-08-19	2022-05-13	苏州普乐康医药科技有限公司	一种抗b7-h3抗体及其应用
CN113337562B (zh) *	2021-05-24	2022-06-03	宁波人健药业集团股份有限公司	使用CHO细胞高效发酵生产rhCG的方法
CN113480632B (zh) *	2021-07-30	2023-02-03	宁波人健药业集团股份有限公司	一种在CHO细胞中表达的重组蛋白rhCG纯化工艺

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4444887A (en)	1979-12-10	1984-04-24	Sloan-Kettering Institute	Process for making human antibody producing B-lymphocytes
US4634665A (en)	1980-02-25	1987-01-06	The Trustees Of Columbia University In The City Of New York	Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5179017A (en)	1980-02-25	1993-01-12	The Trustees Of Columbia University In The City Of New York	Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A (en)	1980-02-25	1983-08-16	The Trustees Of Columbia University	Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4716111A (en)	1982-08-11	1987-12-29	Trustees Of Boston University	Process for producing human antibodies
US4510245A (en)	1982-11-18	1985-04-09	Chiron Corporation	Adenovirus promoter system
GB8308235D0 (en)	1983-03-25	1983-05-05	Celltech Ltd	Polypeptides
US4816567A (en)	1983-04-08	1989-03-28	Genentech, Inc.	Recombinant immunoglobin preparations
US5807715A (en)	1984-08-27	1998-09-15	The Board Of Trustees Of The Leland Stanford Junior University	Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US5168062A (en)	1985-01-30	1992-12-01	University Of Iowa Research Foundation	Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US4968615A (en)	1985-12-18	1990-11-06	Ciba-Geigy Corporation	Deoxyribonucleic acid segment from a virus
GB8607679D0 (en)	1986-03-27	1986-04-30	Winter G P	Recombinant dna product
US5225539A (en)	1986-03-27	1993-07-06	Medical Research Council	Recombinant altered antibodies and methods of making altered antibodies
US5530101A (en)	1988-12-28	1996-06-25	Protein Design Labs, Inc.	Humanized immunoglobulins
US5413923A (en)	1989-07-25	1995-05-09	Cell Genesys, Inc.	Homologous recombination for universal donor cells and chimeric mammalian hosts
GB8928874D0 (en)	1989-12-21	1990-02-28	Celltech Ltd	Humanised antibodies
DE69120146T2 (de)	1990-01-12	1996-12-12	Cell Genesys Inc	Erzeugung xenogener antikörper
GB9015198D0 (en)	1990-07-10	1990-08-29	Brien Caroline J O	Binding substance
US5545806A (en)	1990-08-29	1996-08-13	Genpharm International, Inc.	Ransgenic non-human animals for producing heterologous antibodies
US5814318A (en)	1990-08-29	1998-09-29	Genpharm International Inc.	Transgenic non-human animals for producing heterologous antibodies
US5625126A (en)	1990-08-29	1997-04-29	Genpharm International, Inc.	Transgenic non-human animals for producing heterologous antibodies
US5633425A (en)	1990-08-29	1997-05-27	Genpharm International, Inc.	Transgenic non-human animals capable of producing heterologous antibodies
EP0546073B1 (en)	1990-08-29	1997-09-10	GenPharm International, Inc.	production and use of transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en)	1990-08-29	1997-08-26	Genpharm International Inc.	Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
EP0519596B1 (en)	1991-05-17	2005-02-23	Merck & Co. Inc.	A method for reducing the immunogenicity of antibody variable domains
MX9204374A (es)	1991-07-25	1993-03-01	Idec Pharma Corp	Anticuerpo recombinante y metodo para su produccion.
ES2136092T3 (es)	1991-09-23	1999-11-16	Medical Res Council	Procedimientos para la produccion de anticuerpos humanizados.
ATE275198T1 (de)	1991-12-02	2004-09-15	Medical Res Council	Herstellung von antikörpern auf phagenoberflächen ausgehend von antikörpersegmentbibliotheken.
US5639641A (en)	1992-09-09	1997-06-17	Immunogen Inc.	Resurfacing of rodent antibodies
JP4312259B2 (ja)	1995-04-27	2009-08-12	アムジェンフレモントインク．	免疫したゼノマウス（ＸｅｎｏＭｏｕｓｅ）に由来するヒト抗体
EP0823941A4 (en)	1995-04-28	2001-09-19	Abgenix Inc	HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES
US5705364A (en)	1995-06-06	1998-01-06	Genentech, Inc.	Mammalian cell culture process
US5916771A (en)	1996-10-11	1999-06-29	Abgenix, Inc.	Production of a multimeric protein by cell fusion method
KR20080059467A (ko)	1996-12-03	2008-06-27	아브게닉스, 인크.	복수의 ｖｈ 및 ｖｋ 부위를 함유하는 사람 면역글로불린유전자좌를 갖는 형질전환된 포유류 및 이로부터 생성된항체
PL193780B1 (pl)	1997-04-14	2007-03-30	Micromet Ag	Sposób wytwarzania receptora przeciw ludzkim antygenom, ludzkie przeciwciało i środek farmaceutyczny
US6235883B1 (en)	1997-05-05	2001-05-22	Abgenix, Inc.	Human monoclonal antibodies to epidermal growth factor receptor
DE60230858D1 (de) *	2001-02-15	2009-03-05	Centocor Inc	Chemisch definiertes medium für kultivierte säugerzellen
US7709610B2 (en)	2003-05-08	2010-05-04	Facet Biotech Corporation	Therapeutic use of anti-CS1 antibodies
KR20070009637A (ko)	2004-03-24	2007-01-18	피디엘 바이오파르마 인코포레이티드	암 세포 증식을 억제하는 항α5β1 항체의 용도
AU2005335714B2 (en)	2004-11-10	2012-07-26	Macrogenics, Inc.	Engineering Fc antibody regions to confer effector function
WO2009020933A2 (en)	2007-08-03	2009-02-12	Facet Biotech Corporation	Therapeutic use of anti-tweak receptor antibodies

2012
- 2012-01-12 NO NO14160512A patent/NO2760138T3/no unknown
2013
- 2013-09-27 CA CA2886753A patent/CA2886753C/en active Active
- 2013-09-27 LT LTEP13776656.4T patent/LT2904092T/lt unknown
- 2013-09-27 EP EP13776656.4A patent/EP2904092B1/en active Active
- 2013-09-27 PL PL13776656T patent/PL2904092T3/pl unknown
- 2013-09-27 SI SI201330877T patent/SI2904092T1/en unknown
- 2013-09-27 IN IN2630DEN2015 patent/IN2015DN02630A/en unknown
- 2013-09-27 HU HUE13776656A patent/HUE034896T2/hu unknown
- 2013-09-27 SG SG11201502339YA patent/SG11201502339YA/en unknown
- 2013-09-27 RS RS20171200A patent/RS56641B1/sr unknown
- 2013-09-27 WO PCT/US2013/062410 patent/WO2014055370A1/en active Application Filing
- 2013-09-27 KR KR1020157009991A patent/KR102182885B1/ko active IP Right Grant
- 2013-09-27 ES ES13776656.4T patent/ES2646594T3/es active Active
- 2013-09-27 PT PT137766564T patent/PT2904092T/pt unknown
- 2013-09-27 DK DK13776656.4T patent/DK2904092T3/en active
- 2013-09-27 MX MX2015004027A patent/MX366106B/es active IP Right Grant
- 2013-09-27 SG SG10201702448WA patent/SG10201702448WA/en unknown
- 2013-09-27 EA EA201590550A patent/EA201590550A1/ru unknown
- 2013-09-27 AU AU2013327681A patent/AU2013327681B2/en active Active
- 2013-09-27 CN CN201380058690.XA patent/CN104797707A/zh active Pending
- 2013-09-27 ME MEP-2017-285A patent/ME02882B/me unknown
- 2013-09-27 JP JP2015534771A patent/JP6351598B2/ja active Active
- 2013-09-27 US US14/432,653 patent/US20150259425A1/en not_active Abandoned
- 2013-09-27 BR BR112015007319-0A patent/BR112015007319B1/pt active IP Right Grant
2015
- 2015-03-24 IL IL237916A patent/IL237916A0/en unknown
- 2015-08-18 HK HK15108000.4A patent/HK1207394A1/xx unknown
2017
- 2017-02-03 US US15/424,672 patent/US20170152540A1/en not_active Abandoned
- 2017-11-14 CY CY20171101192T patent/CY1119602T1/el unknown
- 2017-11-14 HR HRP20171753TT patent/HRP20171753T1/hr unknown

Also Published As

Publication number	Publication date
MX2015004027A (es)	2015-10-29
KR20150063441A (ko)	2015-06-09
KR102182885B1 (ko)	2020-11-25
CA2886753C (en)	2021-01-26
JP2015532096A (ja)	2015-11-09
BR112015007319B1 (pt)	2022-02-15
CN104797707A (zh)	2015-07-22
DK2904092T3 (en)	2017-12-11
CA2886753A1 (en)	2014-04-10
EP2904092B1 (en)	2017-09-20
AU2013327681A1 (en)	2015-04-09
HUE034896T2 (hu)	2018-03-28
WO2014055370A1 (en)	2014-04-10
BR112015007319A2 (pt)	2017-08-08
LT2904092T (lt)	2017-12-11
CY1119602T1 (el)	2018-04-04
SI2904092T1 (en)	2018-01-31
IN2015DN02630A (ko)	2015-09-18
EA201590550A1 (ru)	2015-09-30
PL2904092T3 (pl)	2018-02-28
SG11201502339YA (en)	2015-04-29
MX366106B (es)	2019-06-27
US20150259425A1 (en)	2015-09-17
ME02882B (me)	2018-04-20
IL237916A0 (en)	2015-05-31
SG10201702448WA (en)	2017-04-27
US20170152540A1 (en)	2017-06-01
HRP20171753T1 (hr)	2017-12-29
AU2013327681B2 (en)	2019-01-24
PT2904092T (pt)	2017-12-06
HK1207394A1 (en)	2016-01-29
JP6351598B2 (ja)	2018-07-04
EP2904092A1 (en)	2015-08-12
RS56641B1 (sr)	2018-03-30
ES2646594T3 (es)	2017-12-14

Publication	Publication Date	Title
BR112014024221A2 (ko)	2017-06-20
BR112014017635A2 (ko)	2017-06-20
BR112014017614A2 (ko)	2017-06-20
BR112014017625A2 (ko)	2017-06-20
BR112014017659A2 (ko)	2017-06-20
BR112014017646A2 (ko)	2017-06-20
BR112014017638A2 (ko)	2017-06-20
BR112014017607A2 (ko)	2017-06-20
BR112014017634A2 (ko)	2017-06-20
BR112014017609A2 (ko)	2017-06-20
BR112014024034A2 (ko)	2017-06-20
BR112014017644A2 (ko)	2017-06-20
BR112014017647A2 (ko)	2017-06-20
BR112014019572A2 (ko)	2017-06-20
BR112014017618A2 (ko)	2017-06-20
BR112014017630A2 (ko)	2017-06-20
BR112014017652A2 (ko)	2017-06-20
NO2760138T3 (ko)	2018-08-04
BR112014019547A2 (ko)	2017-06-20
BR112014017621A2 (ko)	2017-06-20
BR112014017622A2 (ko)	2017-06-20
BR112014017627A2 (ko)	2017-06-20
BR112014017623A2 (ko)	2017-06-20
BR112014017631A2 (ko)	2017-06-20
BR112014017641A2 (ko)	2017-06-20